Story perspectives

Character Biosciences Raises $93M for AMD Treatments

3/28/2025

29 5

Summary

Story summary

Character Biosciences has raised an impressive $93 million in Series B funding to propel innovative treatments for age-related macular degeneration (AMD), a condition impacting one in eight individuals over 50. This investment will fuel clinical trials for their promising therapies, CTX203 and CTX114. Meanwhile, Ampersand Biomedicines secured $65 million to enhance its AND-Body Therapeutics platform, aiming to tackle diseases with reduced side effects.

1 of 1

Story summary

Character Biosciences has raised an impressive $93 million in Series B funding to propel innovative treatments for age-related macular degeneration (AMD), a condition impacting one in eight individuals over 50. This investment will fuel clinical trials for their promising therapies, CTX203 and CTX114. Meanwhile, Ampersand Biomedicines secured $65 million to enhance its AND-Body Therapeutics platform, aiming to tackle diseases with reduced side effects.